Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

810654

registered interest
date	21/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether his Department plans to introduce automatic insulin delivery devices for people who live with diabetes; and if he will make a statement.
tabling member constituency	South Antrim
tabling member printed	Paul Girvan
uin	120999
answer	answer is ministerial correction date of answer 09/01/2018 answer text <p>Clinical commissioning groups (CCGs) are primarily responsible for commissioning diabetes services. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population, are based on the available evidence, and take into account national guidelines. This would apply to automatic insulin delivery devices, which would need to be both licensed and assessed for clinical and cost-effectiveness.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/01/2018 16:11:10 answering member 4067 label Biography information for Steve Brine
tabling member	4633 label Biography information for Paul Girvan

806205

registered interest
date	13/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment has the Department made of the effectiveness of the introduction of the FreeStyle Libre diabetes system for NHS practitioners.
tabling member constituency	Hendon
tabling member printed	Dr Matthew Offord
uin	119397
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>NHS Business Services Authority carries out the assessment of Part IX applications by manufacturers on behalf of the Secretary of State for Health, for prescribing at National Health Service expense by an appropriate practitioner.</p><p> </p><p>Any device made available for prescribing to patients through listing in Part IX, including FreeStyle Libre, is required to meet set criteria, namely that the product is safe and of good quality, it is appropriate for general practice and, if relevant, non-medical prescribing, and it is cost effective.</p><p> </p><p>However, the listing of a medical device in the Drug Tariff should not be interpreted as a recommendation to prescribe a particular product. Patients will need to discuss the ongoing management of their condition with their healthcare professional and consider whether FreeStyle Libre is appropriate for them.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 21/12/2017 17:01:05 answering member 4067 label Biography information for Steve Brine
tabling member	4006 label Biography information for Dr Matthew Offord

802606

registered interest
date	07/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the efficacy of surgically implanted glucose sensors as a method for controlling Type 1 diabetes.
tabling member constituency	Ipswich
tabling member printed	Sandy Martin
uin	118156
answer	answer is ministerial correction date of answer 14/12/2017 answer text <p>The National Institute for Health and Care Excellence (NICE) has not undertaken an evaluation of the clinical effectiveness of surgically implanted glucose sensors.</p><p> </p><p>Treatments may be brought into routine use in the National Health Service after their efficacy, safety, and cost-effectiveness have been appropriately demonstrated. NICE is responsible for assessing new technologies and interventional procedures, as well as producing guidelines for best practice of treatment and care.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/12/2017 14:25:23 answering member 4067 label Biography information for Steve Brine
tabling member	4678 label Biography information for Sandy Martin

802607

registered interest
date	07/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to encourage Clinical Commissioning Groups to recommend the prescription of surgically implanted glucose sensors for the management of Type 1 diabetes.
tabling member constituency	Ipswich
tabling member printed	Sandy Martin
uin	118157
answer	answer is ministerial correction date of answer 14/12/2017 answer text <p>Surgically implanted glucose sensors are not currently available for prescribing in primary care. To be available for prescribing, a medical device must be listed in Part IX of the England and Wales Drug Tariff.</p><p> </p><p>Any device made available for prescribing to patients through listing in Part IX is required to meet set criteria, namely that the product is safe and of good quality, it is appropriate for general practice and, if relevant, non-medical prescribing, and it is cost effective.</p><p> </p><p>The NHS Business Services Authority carries out the assessment of Part IX applications by manufacturers on behalf of the Secretary of State for Health, for prescribing at National Health Service expense by an appropriate practitioner. However, the listing of a medical device in the Drug Tariff should not be interpreted as a recommendation to prescribe a particular product.</p><p> </p><p>Within its financial constraints, the NHS is committed to providing access to new drugs and medical technologies. Ultimately it is for clinical commissioning groups (CCGs), who are primarily responsible for commissioning diabetes services, to meet the requirements of their population. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population and are based on the available evidence and take into account national guidelines.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/12/2017 14:22:33 answering member 4067 label Biography information for Steve Brine
tabling member	4678 label Biography information for Sandy Martin

802608

registered interest
date	07/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what research his Department has commissioned on the efficacy of surgically implanted glucose monitoring devices for people with Type 1 diabetes.
tabling member constituency	Ipswich
tabling member printed	Sandy Martin
uin	118158
answer	answer is ministerial correction date of answer 14/12/2017 answer text <p>The Department, through the National Institute for Health Research (NIHR), has not commissioned any research on the efficacy of surgically implanted glucose monitoring devices for people with Type 1 diabetes.</p><p> </p><p>The Department’s NIHR welcomes funding applications for research into any aspect of human health, including diabetes; it is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 14/12/2017 14:33:48 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4678 label Biography information for Sandy Martin

794329

registered interest
date	23/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to ensure that the FreeStyle Libre Flash Glucose Monitoring system is accessible to all diabetes patients
tabling member constituency	Crewe and Nantwich
tabling member printed	Laura Smith
uin	115302
answer	answer is ministerial correction date of answer 01/12/2017 answer text <p>Freestyle Libre has been approved for reimbursement on National Health Service prescription from 1 November through listing in Part IX of the Drug Tariff. The Drug Tariff is a price list that covers England and Wales, and the listing of a medical device in the Tariff should not be interpreted as a recommendation to prescribe a particular product. Patients will need to discuss the ongoing management of their condition with their healthcare professional and consider whether flash glucose monitoring is suitable for them.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 01/12/2017 13:00:42 answering member 4067 label Biography information for Steve Brine
tabling member	4648 label Biography information for Laura Smith

793541

registered interest
date	22/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes: Medical Equipment
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether the National Institute for Health and Care Excellence has undertaken any evaluation of glucose monitors used by people living with diabetes; if so, whether such monitors are approved for use; and what assessment they have made of the decision taken by some Clinical Commissioning Groups not to prescribe such monitors to diabetes patients.
tabling member printed	Lord Morris of Aberavon
uin	HL3502
answer	answer is ministerial correction date of answer 06/12/2017 answer text <p>The National Institute for Health and Care Excellence (NICE) has evaluated the following glucose monitors used by people living with diabetes:</p><p> </p><p>- Integrated sensor-augmented pump therapy systems for managing blood glucose levels in type 1 diabetes (the MiniMed Paradigm Veo system and the Vibe and G4 PLATINUM CGM system). NICE has evaluated these products through its diagnostics programme. The MiniMed Paradigm Veo system is recommended as an option for managing blood glucose levels in people with type 1 diabetes only if they have episodes of disabling hypoglycaemia despite optimal management with continuous subcutaneous insulin infusion.</p><p> </p><p>- MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes. This is a NICE advice product, developed under its Medtech innovation briefings (MIBs) programme. MIBs provide a summary of the best available evidence for selected new technologies and are designed to assist National Health Service planning and decision-making. MIBs are not designed to include treatment advice but provide a critical review of the strengths and weaknesses of the relevant evidence, therefore NICE do not make any recommendations for (or against) funding the device.</p><p> </p><p>- FreeStyle Libre for glucose monitoring, which measures interstitial fluid glucose levels in people with diabetes. This is also a Medtech innovation briefing therefore NICE do not make any recommendations for funding the device.</p><p> </p><p>In addition, the Regional Medicines Optimisation Committee (North), one of four Committees established by NHS England to provide advice to the NHS, reviewed the use of the Freestyle Libre at its meeting on 26 October 2017. In developing its advice, the Committee took into account the MIB published by NICE. The Committee has issued guidance on the use of Freestyle Libre suggesting a careful start to its use and data collection to better understand the benefits. Freestyle Libre has been approved for reimbursement on NHS prescription from 1 November through listing in Part IX of the Drug Tariff.</p><p><strong> </strong></p><p>NICE does not have a role in proactively monitoring the delivery of local services, so it has not made any assessment of decisions taken by some clinical commissioning groups not to fund these technologies.</p> answering member printed Lord O'Shaughnessy question first answered 06/12/2017 13:29:52 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	565 label Biography information for Lord Morris of Aberavon

778221

registered interest
date	26/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effect of flash glucose monitoring on the management of diabetes.
tabling member constituency	Tynemouth
tabling member printed	Mr Alan Campbell
uin	109900
answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>Freestyle Libre, a flash glucose monitoring system has been approved for reimbursement on National Health Service prescription from 1 November 2017 through listing in Part IX of the NHS England and Wales Drug Tariff.</p><p> </p><p>The NHS Business Services Authority carries out the assessment of Part IX applications made by manufacturers on behalf, of the Secretary of State for Health, for prescribing at NHS expense by an appropriate practitioner.</p><p> </p><p>The listing of a medical device in the Drug Tariff should not be interpreted as a recommendation to prescribe a particular product. Patients will need to discuss the ongoing management of their condition with their healthcare professional and consider whether flash glucose monitoring is suitable for them.</p><p> </p><p>Any device made available for prescribing to patients through listing in Part IX is required to meet set criteria, namely that the product is safe and of good quality, it is appropriate for general practice and, if relevant, non-medical prescribing, and it is cost effective.</p><p> </p><p>Within its financial constraints, the NHS is committed to providing access to new drugs and medical technologies. Ultimately it is for clinical commissioning groups (CCGs), who are primarily responsible for commissioning diabetes services, to meet the requirements of their population. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population and are based on the available evidence and take into account national guidelines.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 109901 question first answered 03/11/2017 11:47:02 answering member 4067 label Biography information for Steve Brine
tabling member	529 label Biography information for Sir Alan Campbell

778222

registered interest
date	26/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department takes to ensure that people with diabetes have access to new and emerging technologies as they come to market.
tabling member constituency	Tynemouth
tabling member printed	Mr Alan Campbell
uin	109901
answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>Freestyle Libre, a flash glucose monitoring system has been approved for reimbursement on National Health Service prescription from 1 November 2017 through listing in Part IX of the NHS England and Wales Drug Tariff.</p><p> </p><p>The NHS Business Services Authority carries out the assessment of Part IX applications made by manufacturers on behalf, of the Secretary of State for Health, for prescribing at NHS expense by an appropriate practitioner.</p><p> </p><p>The listing of a medical device in the Drug Tariff should not be interpreted as a recommendation to prescribe a particular product. Patients will need to discuss the ongoing management of their condition with their healthcare professional and consider whether flash glucose monitoring is suitable for them.</p><p> </p><p>Any device made available for prescribing to patients through listing in Part IX is required to meet set criteria, namely that the product is safe and of good quality, it is appropriate for general practice and, if relevant, non-medical prescribing, and it is cost effective.</p><p> </p><p>Within its financial constraints, the NHS is committed to providing access to new drugs and medical technologies. Ultimately it is for clinical commissioning groups (CCGs), who are primarily responsible for commissioning diabetes services, to meet the requirements of their population. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population and are based on the available evidence and take into account national guidelines.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 109900 question first answered 03/11/2017 11:47:02 answering member 4067 label Biography information for Steve Brine
tabling member	529 label Biography information for Sir Alan Campbell

712468

registered interest
date	20/03/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make it his policy to make continuous glucose monitors available on the NHS.
tabling member constituency	Wellingborough
tabling member printed	Mr Peter Bone
uin	68467
answer	answer is ministerial correction date of answer 23/03/2017 answer text <p>Clinical commissioning groups (CCGs) are primarily responsible for commissioning diabetes services to meet the requirements of their populations. In doing so, CCGs need to ensure that the services they provide are fit for purpose, reflect the needs of the local population, and are based on the available evidence, taking into account national guidelines. This should include consideration of access to continuous glucose monitoring for people with type 1 diabetes who might benefit from it.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 23/03/2017 09:48:15 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1581 label Biography information for Mr Peter Bone